The abstract is read at the publisher; the summary is JClub's.
In ARMMS-T2D, 58% of 166 participants randomized to metabolic-bariatric surgery achieved type 2 diabetes remission versus 3% with medical-lifestyle management over a median 11-year follow-up.
- Why it matters: Remission after metabolic-bariatric surgery is not universal, and relapse can occur, so clinicians need baseline markers to better match patients to treatment strategies.
- What they did: The 14-year multicenter study analyzed predictors of remission (HbA1c <6.5% without glucose-lowering drugs) and relapse using univariate time-to-event tests and multivariate least absolute shrinkage and selection operator models.
- The result: In multivariate analyses, baseline diabetes duration, insulin use, and 1-year weight change predicted remission (all P < 0.01), while relapse after remission in the MBS group was predicted by longer baseline diabetes duration and more glucose-lowering medication classes used.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.